A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Hospital Los Angeles
Age
1–20
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: Patients must be \> 12 months and \< 21 years of age at the time of study entry.
Weight: Patient must be more than or equal to 10 Kilograms.
Histological Diagnosis:
Patients must have had histological verification of the malignancy at some time prior to study entry.
All solid tumors are eligible with the exclusion of lymphomas. For patients with neuroblastoma, diagnosis based on elevated catecholamines in the urine and tumor cells on bone marrow aspirates/biopsies is acceptable.
For patients with germ cell tumors, diagnosis based on elevated tumor markers (serum alpha fetoprotein and/or serum beta human chorionic gonadotropin) and radiographic evidence of disease is acceptable.
Disease Status:
Disease must have failed standard therapy (therapies) or be a disease for which no standard therapy exists.
You may not be if
Performance Level:
Karnofsky \> 50% for patients \>16 years of age and Lansky \> 50 for children \< 16 years of age (Appendix I).
Life Expectancy: Must be \> 8 weeks.
Patients who have received bevacizumab and/or Irinotecan previously are ineligible. Non brain tumor patients who have previously received Temozolomide are ineligible.
Pregnancy or Breast-Feeding: Pregnant patients are ineligible for this study due to the known teratogenic effects of the cytotoxic agents. Pregnancy tests must be obtained in females of childbearing potential prior to enrollment.
Lactating women must agree not to breast-feed.
Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.
Patients Who Have an Uncontrolled Infection will not be eligible for enrollment until all infections are under control.
Clinically Significant Unrelated Systemic Illness: Patients with serious infections or significant pulmonary, hepatic, renal, or other end-organ dysfunction which in the judgment of the Principal or Co-Investigators would compromise the patient's ability to tolerate prescribed chemotherapy or are likely to interfere with the study procedures or results will not be eligible.
Clareo Health | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
